What are the risks of MPT?

Acute Toxicity No formal data. Safety profile inferred from class membership. Based on analogy to DMT, MET, and other N-methyl-N-alkyl tryptamines, acute physiological toxicity at psychedelic doses is presumed low. Risks Standard tryptamine class risks apply: sympathomimetic effects, psychological r

MPT — SubstanceWiki

N-Methyl-N-propyltryptamine (MPT) is a synthetic psychedelic tryptamine belonging to the N-methyl-N-alkyl substituted tryptamine family, structurally related to DMT and MET. The compound features one methyl and one propyl group on the terminal nitrogen of the tryptamine core. Like MET, it is expected to demonstrate partial oral bioavailability due to reduced MAO-A affinity compared to DMT.

MPT occupies a relatively obscure position in the psychedelic tryptamine literature. Alexander Shulgin documented it in TiHKAL alongside other N-methyl-N-alkyl tryptamines, but it has not attracted the community interest of MET or the well-characterized 4-AcO/4-HO analogs. Community experience documentation is sparse, and formal pharmacological data is essentially absent. The compound is a logical structural data point in mapping the N-alkyl tryptamine structure-activity relationship, positioned between MET (methyl-ethyl) and the higher methyl-alkyl analogs.

Based on class membership and structural analogy, MPT is presumed to act as a 5-HT2A partial agonist producing psychedelic effects broadly consistent with the tryptamine class — visual phenomena, altered cognition, and emotional amplification. Duration and dose parameters are not well established in the community, and the limited available data should be approached with appropriate caution.

How It Feels

The onset of MPT establishes itself within twenty to forty minutes as a growing visual brightness and a moderate body buzz. Colors begin to sharpen and saturate, edges become more defined, and surfaces acquire a subtle luminosity. A tingling warmth builds in the torso and extremities, accompanied by a mild increase in heart rate and a slight tension in the jaw. The transition from baseline is steady and confident — neither as abrupt as DMT-like compounds nor as gradual as the gentlest tryptamines.

Over the next thirty to sixty minutes, the visual effects develop to a moderate plateau. Surfaces display a gentle breathing quality and may show soft geometric patterning — repeating motifs that overlay textures without obscuring them. Colors become noticeably more vivid, particularly warm tones, which seem to glow with an inner light. Closed-eye visuals offer more complexity: structured geometric forms, flowing patterns of color, and occasional dreamlike imagery that shifts with thought and mood. The visual character sits comfortably between the crystalline precision of DET and the flowing organicism of psilocin-type compounds — balanced, moderate, and aesthetically pleasing.

The peak arrives around sixty to ninety minutes and holds for two to three hours. The headspace is moderately altered: thoughts are more associative and reflective than usual, and there is a gentle expansion of awareness that encourages contemplation without compelling it. Emotional tone is generally positive, with a mild euphoria and a sense of quiet wellbeing. Cognitive function is not significantly impaired — conversations are manageable, and the user retains a clear sense of their state and surroundings. The body feels comfortable and mildly stimulated, with a pleasant warmth and a moderate energy level.

The comedown is gradual and uncomplicated, the visual enhancement and altered headspace fading smoothly over one to two hours. The total duration is four to six hours. The afterglow is mild — a subtle brightness of mood and a residual visual clarity that may last a few hours. MPT is a middle-of-the-road tryptamine in the truest sense: moderate in duration, intensity, and character, offering a reliable and balanced psychedelic experience that neither overwhelms nor underwhelms.

Detection Methods

Urine Detection

MPT is not targeted by standard immunoassay-based urine drug screens. As a tryptamine, it is metabolized through monoamine oxidase pathways and produces hydroxylated and deaminated metabolites that are excreted renally. Specialized LC-MS/MS methods can detect tryptamine metabolites in urine for approximately 24 to 48 hours after ingestion. The short duration of action of most base tryptamines results in a relatively brief detection window compared to longer-acting psychoactive substances.

Blood and Serum Detection

Blood detection windows for MPT are short, typically 4 to 12 hours after oral administration. If smoked or insufflated, peak concentrations occur within minutes and clearance is more rapid. LC-MS/MS is required for reliable blood detection at the low concentrations characteristic of tryptamine compounds. The rapid metabolism by MAO-A significantly limits the time window in which blood sampling can capture meaningful concentrations.

Standard Drug Panel Inclusion

MPT is NOT included on standard 5-panel, 10-panel, or 12-panel drug screens. Tryptamines do not cross-react with immunoassay targets for amphetamines, cannabinoids, cocaine metabolites, opiates, PCP, or any other standard panel analyte. Detection requires specific testing at a reference laboratory capable of novel psychoactive substance analysis. Even extended clinical panels rarely include base tryptamines.

Confirmatory Methods

Confirmatory identification of MPT relies on LC-MS/MS or GC-MS with appropriate reference standards. GC-MS analysis of tryptamines may require derivatization for optimal sensitivity and chromatographic performance. Reference laboratories specializing in novel psychoactive substances provide the most comprehensive detection capabilities. Standard clinical toxicology laboratories generally do not maintain validated methods for base tryptamines.

Reagent Testing (Harm Reduction)

The Ehrlich reagent produces a purple to violet reaction with MPT, confirming the presence of an indole ring system. This is the primary field identification tool and should be used as the first screening test. The Hofmann reagent provides a confirmatory blue to purple reaction. The Marquis reagent typically shows no reaction or a slight brown-yellow discoloration with base tryptamines. A positive Ehrlich result confirms the tryptamine class but does not identify the specific compound. Multiple reagents should be used together for greater confidence in identification.

Interactions

Substance	Status	Note
2-Aminoindane	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
2-FA	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
2-FEA	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
2-FMA	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
2,5-DMA	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
2C-H	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
3-FA	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
3-FEA	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
3-FMA	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
3-FPM	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
3-MMC	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
3,4-CTMP	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
4-FA	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
4-FMA	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
4-MMC	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
4F-EPH	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
4F-MPH	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
5-APB	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
5F-AKB48	Caution	Cannabis can unpredictably intensify psychedelic effects and increase anxiety
5F-PB-22	Caution	Cannabis can unpredictably intensify psychedelic effects and increase anxiety
6-APDB	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
8-Chlorotheophylline	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
A-PHP	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
A-PVP	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
AB-FUBINACA	Caution	Cannabis can unpredictably intensify psychedelic effects and increase anxiety
Adrafinil	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Amphetamine	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Anandamide	Caution	Cannabis can unpredictably intensify psychedelic effects and increase anxiety
APICA	Caution	Cannabis can unpredictably intensify psychedelic effects and increase anxiety
Armodafinil	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Atropa belladonna	Caution	Unpredictable compounding of hallucinogenic effects with anticholinergic delirium
Benzydamine	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Bromantane	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Butylone	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Caffeine	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Cannabidiol	Caution	Cannabis can unpredictably intensify psychedelic effects and increase anxiety
Cannabis	Caution	Cannabis can unpredictably intensify psychedelic effects and increase anxiety
Cocaine	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Cyclazodone	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Datura	Caution	Unpredictable compounding of hallucinogenic effects with anticholinergic delirium
Desoxypipradrol	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Dextroamphetamine	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Dichloropane	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Diphenhydramine	Caution	Unpredictable compounding of hallucinogenic effects with anticholinergic delirium
Ephedrine	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Ephylone	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
ETH-CAT	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Ethylone	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Ethylphenidate	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Fenethylline	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Harmala alkaloid	Caution	MAOIs dramatically potentiate psychedelics; drastically reduce dose and exercise extreme caution
Hexedrone	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Isopropylphenidate	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
JWH-018	Caution	Cannabis can unpredictably intensify psychedelic effects and increase anxiety
JWH-073	Caution	Cannabis can unpredictably intensify psychedelic effects and increase anxiety
Kratom	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Lisdexamfetamine	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
MAOI	Caution	MAOIs dramatically potentiate psychedelics; drastically reduce dose and exercise extreme caution
MCPP	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
MDA	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
MDMA	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
MDPV	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Mephedrone	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Methamphetamine	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Methcathinone	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Methiopropamine	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Methylnaphthidate	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Methylone	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Methylphenidate	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Mexedrone	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Mirtazapine	Caution	Unpredictable compounding of hallucinogenic effects with anticholinergic delirium
Modafinil	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Myristicin	Caution	Unpredictable compounding of hallucinogenic effects with anticholinergic delirium
N-Ethylhexedrone	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
N-Methylbisfluoromodafinil	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
NEP	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Nicotine	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
NM-2-AI	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Oxiracetam	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Peganum harmala	Caution	MAOIs dramatically potentiate psychedelics; drastically reduce dose and exercise extreme caution
Pentedrone	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Phenylpiracetam	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Rhodiola Rosea	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
1,3-Butanediol	Low Risk & Synergy	Cross-tolerance exists; effects compound
1B-LSD	Low Risk & Synergy	Cross-tolerance exists; effects compound
1cP-AL-LAD	Low Risk & Synergy	Cross-tolerance exists; effects compound
1cP-LSD	Low Risk & Synergy	Cross-tolerance exists; effects compound
1cP-MiPLA	Low Risk & Synergy	Cross-tolerance exists; effects compound
1P-ETH-LAD	Low Risk & Synergy	Cross-tolerance exists; effects compound
1P-LSD	Low Risk & Synergy	Cross-tolerance exists; effects compound
1V-LSD	Low Risk & Synergy	Cross-tolerance exists; effects compound
2-Fluorodeschloroketamine	Low Risk & Synergy	Produces unique synergistic effects; often combined
25B-NBOH	Low Risk & Synergy	Cross-tolerance exists; effects compound
25B-NBOMe	Low Risk & Synergy	Cross-tolerance exists; effects compound
25C-NBOH	Low Risk & Synergy	Cross-tolerance exists; effects compound
25C-NBOMe	Low Risk & Synergy	Cross-tolerance exists; effects compound
25D-NBOMe	Low Risk & Synergy	Cross-tolerance exists; effects compound
25E-NBOH	Low Risk & Synergy	Cross-tolerance exists; effects compound
25I-NBOH	Low Risk & Synergy	Cross-tolerance exists; effects compound
25I-NBOMe	Low Risk & Synergy	Cross-tolerance exists; effects compound
25N-NBOMe	Low Risk & Synergy	Cross-tolerance exists; effects compound
2C-B	Low Risk & Synergy	Cross-tolerance exists; effects compound
2C-B-FLY	Low Risk & Synergy	Cross-tolerance exists; effects compound
2C-C	Low Risk & Synergy	Cross-tolerance exists; effects compound
2C-D	Low Risk & Synergy	Cross-tolerance exists; effects compound
2C-E	Low Risk & Synergy	Cross-tolerance exists; effects compound
2C-I	Low Risk & Synergy	Cross-tolerance exists; effects compound
2C-P	Low Risk & Synergy	Cross-tolerance exists; effects compound
2C-T	Low Risk & Synergy	Cross-tolerance exists; effects compound
2C-T-2	Low Risk & Synergy	Cross-tolerance exists; effects compound
2C-T-21	Low Risk & Synergy	Cross-tolerance exists; effects compound
2C-T-7	Low Risk & Synergy	Cross-tolerance exists; effects compound
3-Cl-PCP	Low Risk & Synergy	Produces unique synergistic effects; often combined
3-HO-PCE	Low Risk & Synergy	Produces unique synergistic effects; often combined
3-HO-PCP	Low Risk & Synergy	Produces unique synergistic effects; often combined
3-MeO-PCE	Low Risk & Synergy	Produces unique synergistic effects; often combined
3-MeO-PCMo	Low Risk & Synergy	Produces unique synergistic effects; often combined
3-MeO-PCP	Low Risk & Synergy	Produces unique synergistic effects; often combined
3C-E	Low Risk & Synergy	Cross-tolerance exists; effects compound
3C-P	Low Risk & Synergy	Cross-tolerance exists; effects compound
4-AcO-DET	Low Risk & Synergy	Cross-tolerance exists; effects compound
4-AcO-DiPT	Low Risk & Synergy	Cross-tolerance exists; effects compound
4-AcO-DMT	Low Risk & Synergy	Cross-tolerance exists; effects compound
4-AcO-MET	Low Risk & Synergy	Cross-tolerance exists; effects compound
4-AcO-MiPT	Low Risk & Synergy	Cross-tolerance exists; effects compound
4-HO-DET	Low Risk & Synergy	Cross-tolerance exists; effects compound
4-HO-DiPT	Low Risk & Synergy	Cross-tolerance exists; effects compound
4-HO-DPT	Low Risk & Synergy	Cross-tolerance exists; effects compound
4-HO-EPT	Low Risk & Synergy	Cross-tolerance exists; effects compound
4-HO-MET	Low Risk & Synergy	Cross-tolerance exists; effects compound
4-HO-MiPT	Low Risk & Synergy	Cross-tolerance exists; effects compound
4-HO-MPT	Low Risk & Synergy	Cross-tolerance exists; effects compound
4-MeO-PCP	Low Risk & Synergy	Produces unique synergistic effects; often combined
5-MeO-DALT	Low Risk & Synergy	Cross-tolerance exists; effects compound
5-MeO-DiBF	Low Risk & Synergy	Cross-tolerance exists; effects compound
5-MeO-DiPT	Low Risk & Synergy	Cross-tolerance exists; effects compound
5-MeO-DMT	Low Risk & Synergy	Cross-tolerance exists; effects compound
5-MeO-MiPT	Low Risk & Synergy	Cross-tolerance exists; effects compound
6-APB	Low Risk & Synergy	Cross-tolerance exists; effects compound
AL-LAD	Low Risk & Synergy	Cross-tolerance exists; effects compound
ALD-52	Low Risk & Synergy	Cross-tolerance exists; effects compound
Allylescaline	Low Risk & Synergy	Cross-tolerance exists; effects compound
Ayahuasca	Low Risk & Synergy	Cross-tolerance exists; effects compound
Bromo-DragonFLY	Low Risk & Synergy	Cross-tolerance exists; effects compound
Bufotenin	Low Risk & Synergy	Cross-tolerance exists; effects compound
Deschloroketamine	Low Risk & Synergy	Produces unique synergistic effects; often combined
DET	Low Risk & Synergy	Cross-tolerance exists; effects compound
Dextromethorphan	Low Risk & Synergy	Produces unique synergistic effects; often combined
Diphenidine	Low Risk & Synergy	Produces unique synergistic effects; often combined
DiPT	Low Risk & Synergy	Cross-tolerance exists; effects compound
DMT	Low Risk & Synergy	Cross-tolerance exists; effects compound
DOB	Low Risk & Synergy	Cross-tolerance exists; effects compound
DOC	Low Risk & Synergy	Cross-tolerance exists; effects compound
DOI	Low Risk & Synergy	Cross-tolerance exists; effects compound
DOM	Low Risk & Synergy	Cross-tolerance exists; effects compound
DPT	Low Risk & Synergy	Cross-tolerance exists; effects compound
Efavirenz	Low Risk & Synergy	Cross-tolerance exists; effects compound
Ephenidine	Low Risk & Synergy	Produces unique synergistic effects; often combined
EPT	Low Risk & Synergy	Cross-tolerance exists; effects compound
Escaline	Low Risk & Synergy	Cross-tolerance exists; effects compound
ETH-LAD	Low Risk & Synergy	Cross-tolerance exists; effects compound
HXE	Low Risk & Synergy	Produces unique synergistic effects; often combined
Ibogaine	Low Risk & Synergy	Cross-tolerance exists; effects compound
Inhalants	Low Risk & Synergy	Produces unique synergistic effects; often combined
Ketamine	Low Risk & Synergy	Produces unique synergistic effects; often combined
LAE-32	Low Risk & Synergy	Cross-tolerance exists; effects compound
LSA	Low Risk & Synergy	Cross-tolerance exists; effects compound
LSD	Low Risk & Synergy	Cross-tolerance exists; effects compound
LSM-775	Low Risk & Synergy	Cross-tolerance exists; effects compound
LSZ	Low Risk & Synergy	Cross-tolerance exists; effects compound
Memantine	Low Risk & Synergy	Produces unique synergistic effects; often combined
Mescaline	Low Risk & Synergy	Cross-tolerance exists; effects compound
MET	Low Risk & Synergy	Cross-tolerance exists; effects compound
Methallylescaline	Low Risk & Synergy	Cross-tolerance exists; effects compound
Methoxetamine	Low Risk & Synergy	Produces unique synergistic effects; often combined
Methoxphenidine	Low Risk & Synergy	Produces unique synergistic effects; often combined
MiPLA	Low Risk & Synergy	Cross-tolerance exists; effects compound
MiPT	Low Risk & Synergy	Cross-tolerance exists; effects compound
MXiPr	Low Risk & Synergy	Produces unique synergistic effects; often combined
Nitrous	Low Risk & Synergy	Produces unique synergistic effects; often combined
O-PCE	Low Risk & Synergy	Produces unique synergistic effects; often combined
PARGY-LAD	Low Risk & Synergy	Cross-tolerance exists; effects compound
PCE	Low Risk & Synergy	Produces unique synergistic effects; often combined
PCP	Low Risk & Synergy	Produces unique synergistic effects; often combined
PRO-LAD	Low Risk & Synergy	Cross-tolerance exists; effects compound
Psilocybin Mushrooms	Low Risk & Synergy	Cross-tolerance exists; effects compound
Codeine	Low Risk & No Synergy	No significant pharmacological interaction; opioids may slightly dull the psychedelic experience
Fentanyl	Low Risk & No Synergy	No significant pharmacological interaction; opioids may slightly dull the psychedelic experience
Heroin	Low Risk & No Synergy	No significant pharmacological interaction; opioids may slightly dull the psychedelic experience
Morphine	Low Risk & No Synergy	No significant pharmacological interaction; opioids may slightly dull the psychedelic experience
Oxycodone	Low Risk & No Synergy	No significant pharmacological interaction; opioids may slightly dull the psychedelic experience
Alcohol	Low Risk & Decrease	Depressants dull psychedelic effects; benzodiazepines are commonly used as trip-killers
Alprazolam	Low Risk & Decrease	Depressants dull psychedelic effects; benzodiazepines are commonly used as trip-killers
Clonazepam	Low Risk & Decrease	Depressants dull psychedelic effects; benzodiazepines are commonly used as trip-killers
Diazepam	Low Risk & Decrease	Depressants dull psychedelic effects; benzodiazepines are commonly used as trip-killers
GHB	Low Risk & Decrease	Depressants dull psychedelic effects; benzodiazepines are commonly used as trip-killers
Lorazepam	Low Risk & Decrease	Depressants dull psychedelic effects; benzodiazepines are commonly used as trip-killers

Showing 197 key interactions out of 240 total.

Full	almost immediately after ingestion
Half	3 days
Zero	7 days

MPT

Dosage

Duration

How It Feels

Subjective Effects

Physical Effects

Physical(3)

Cognitive & Perceptual Effects

Visual(16)

Pharmacology

Mechanism of Action

Oral Activity

Pharmacokinetics

Detection Methods

Urine Detection

Blood and Serum Detection

Standard Drug Panel Inclusion

Confirmatory Methods

Reagent Testing (Harm Reduction)

Interactions

History

Shulgin Documentation

Current Status

Harm Reduction

Caution Given Limited Documentation

Dosing

Standard Approach

Toxicity & Safety

Acute Toxicity

Risks

Addiction Potential

Overdose Information

Tolerance

Cross-tolerances

Legal Status

Experience Reports (2)

Tips (3)

See Also

References (4)

Frequently Asked Questions

Cognitive(9)

Transpersonal(2)